Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
Robert M. Anthenelli(University of California San Diego), A. Eden Evins(Massachusetts General Hospital), Alok Krishen(PAREXEL International (United States)), David Lawrence(Pfizer (United States)), Robert West(The Behaviouralist (United Kingdom)), Thomas McRae(Pfizer (United States)), Neal L. Benowitz(University of California, San Francisco), Cristina Russ(Pfizer (United States)), John A. Ascher(Research Triangle Park Foundation), Lisa St Aubin(Pfizer (United States))
Cited by 1,170
Related Papers
Biochemical verification of tobacco use and cessation
|Nicotine & Tobacco Research|2002|1.8k
Levels of selected carcinogens and toxicants in vapour from electronic cigarettes
|Tobacco Control|2013|1.7k
Metabolism and Disposition Kinetics of Nicotine
|Pharmacological Reviews|2005|1.6k
Nicotine Addiction
|New England Journal of Medicine|2010|1.5k
Nicotine Chemistry, Metabolism, Kinetics and Biomarkers
|Handbook of experimental pharmacology|2009|1.4k